Overview

Over the past two decades the benefits of label-free biosensor analysis have begun to make an impact in the market, and systems are beginning to be used as mainstream research tools in many drug discovery laboratories. Label-Free Technologies For Drug Discovery summarises the latest and emerging developments in label-free detection systems, their underlying technology principles and end-user case studies that reveal the power and limitations of label-free in all areas of drug discovery. Label-free technologies discussed include SPR, NMR, high-throughput mass spectrometry, resonant waveguide plate-based screening, transmitted-light imaging, isothermal titration calorimetry, optical and impedance cell-based assays and other biophysical methods. The technologies are discussed in relation to their use as screening technologies, high-content technologies, hit finding and hit validation strategies, mode of action and ADME/T, access to difficult target classes, cell-based receptor/ligand interactions particularly orphan receptors, and antibody and small molecule affinity and kinetic analysis. Label-Free Technologies For Drug Discovery is an essential guide to this emerging class of tools for researchers in drug discovery and development, particularly high-throughput screening and compound profiling teams, medicinal chemists, structural biologists, assay developers, ADME/T specialists, and others interested in biomolecular interaction analysis.

Full Product Details

9780470746837

Table of Contents

Reviews

Label-Free Technologies For Drug Discovery summarises the latest and emerging developments in label-free detection systems, their underlying technology principles and end-user case studies that reveal the power and limitations of label-free in all areas of drug discovery. ( Laboratory Journal , 10 March 2011)

Label-Free Technologies For Drug Discovery summarises the latest and emerging developments in label-free detection systems, their underlying technology principles and end-user case studies that reveal the power and limitations of label-free in all areas of drug discovery. (Laboratory Journal, 10 March 2011)

Author Information

Dr Matthew Cooper, Institute for Molecular Bioscience, University of Queensland, Australia Dr Cooper is a scientist and entrepreneur. He is Co-Founder and Chief Scientific Officer of Akubio Ltd; and Founder and Managing Director of Cambridge Medical Innovations. He has written more than 60 publications and invited reviews in leading scientific journals including Nature Biotechnology, Nature Cell Biology, and Nature Drug Discovery. Dr Lorenz M. Mayr, Biology Unit, Protease Platform, Novartis Pharma AG, Basel, Switzerland Dr Mayer is Head of the Biology Unit at the Protease Platform, Centre of Proteomic Chemistry (CPC), at Novartis Pharma AG with responsibility for target finding and target validation, protein expression, assay development and compound screening and profiling for all protease projects. Dr. Mayr is a member of several editorial and scientific advisory boards and also serves as a member at the Board of Directors of SBS, the Society of Biomolecular Sciences.

Tab Content 6

Countries Available